Senju C*, Nakazawa Y*, Oso T*, Shimada M, Kato K, Matsuse M, Tsujimoto M, Masaki T, Miyazaki Y, Fukushima S, Tateishi S, Utani A, Murota H, Tanaka K, Mitsutake N, Moriwaki S, Nishigori C, and Ogi T, 2023. Deep intronic founder mutations identified in the ERCC4/ XPF gene are potential therapeutic targets for a high-frequency form of xeroderma pigmentosum.  Proc Natl Acad Sci U S A;2023 Jul 4;120(27).

Nakazawa Y, Hara Y, Oka Y, Komine O, Heuvel D, Guo C, Daigaku Y, Isono M, He Y, Shimada M, Katoh K, Jia N, Hashimoto S, Kotani Y, Miyoshi Y, Tanaka M, Sobue A, Mitsutake N, Suganami T, Masuda A, Ohno K, Nakada S, Mashimo T, Yamanaka K, Luijsterburg M, Ogi T§. Ubiquitination of DNA Damage-Stalled RNAPII Promotes Transcription-Coupled Repair.  Cell 180(6): 1228-1244 (2020). doi: 10.1016/j.cell.2020.02.010.

Oka Y, Hamada M*, Nakazawa Y *, Muramatsu H*, Okuno Y*, Higasa K*, Shimada M, Takeshima H, Hanada K, Hirano T, Kawakita T, Sakaguchi H, Ichimura T, Ozono S, Yuge K, Watanabe Y, Kotani Y, Yamane M, Kasugai Y, Tanaka M, Suganami T, Nakada S, Mitsutake N, Hara Y, Kato K, Mizuno S, Miyake N, Kawai Y, Tokunaga K, Nagasaki M, Kito S, Isoyama K, Onodera M, Kaneko H, Matsumoto N, Matsuda F, Matsuo K, Takahashi Y, Mashimo T, Kojima S, Ogi T§. Digenic mutations in ALDH2 and ADH5 impair formaldehyde clearance and cause a multisystem disorder, AMeD syndrome.  Science Advances 6(51): eabd7197 (2020). doi: 10.1126/sciadv.abd7197.

Ono R; Masaki T; Mayca Pozo F; Nakazawa Y; Swagemakers SM; Nakano E; Sakai W; Takeuchi S; Kanda F; Ogi T; van der Spek PJ; Sugasawa K; Nishigori C, 2016. A 10-year follow-up of a child with mild case of xeroderma pigmentosum complementation group D diagnosed by whole-genome sequencing.  Photodermatol Photoimmunol Photomed.

Jia N; Nakazawa Y; Guo C; Shimada M; Sethi M; Takahashi Y; Ueda H; Nagayama Y; Ogi T, 2015. A rapid, comprehensive system for assaying DNA repair activity and cytotoxic effects of DNA-damaging reagents.  Nat Protoc 10(1):12-24

Tamura S; Higuchi K; Tamaki M; Inoue C; Awazawa R; Mitsuki N; Nakazawa Y; Mishima H; Takahashi K; Kondo O; Imai K; Morio T; Ohara O; Ogi T; Furukawa F; Inoue M; Yoshiura K; Kanazawa N, 2015. Novel compound heterozygous DNA ligase IV mutations in an adolescent with a slowly-progressing radiosensitive-severe combined immunodeficiency.  Clin Immunol 160(2):255-60

Guo CY; Luo L; Urata Y; Goto S; Huang WJ; Takamura S; Hayashi F; Doi H; Kitajima Y; Ono Y; Ogi T; Li TS, 2015. Sensitivity and dose dependency of radiation-induced injury in hematopoietic stem/progenitor cells in mice.  Sci Rep 5:8055

Alagoz M; Katsuki Y; Ogiwara H; Ogi T; Shibata A; Kakarougkas A; Jeggo P, 2015. SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells.  Nucleic Acids Res 43(16):7931-44

Guo C; Nakazawa Y; Woodbine L; Björkman A; Shimada M; Fawcett H; Jia N; Ohyama K; Li TS; Nagayama Y; Mitsutake N; Pan-Hammarström Q; Gennery AR; Lehmann AR; Jeggo PA; Ogi T, 2015. XRCC4 deficiency in human subjects causes a marked neurological phenotype but no overt immunodeficiency.  J Allergy Clin Immunol 136(4):1007-17

Baple EL; Chambers H; Cross HE; Fawcett H; Nakazawa Y; Chioza BA; Harlalka GV; Mansour S; Sreekantan-Nair A; Patton MA; Muggenthaler M; Rich P; Wagner K; Coblentz R; Stein CK; Last JI; Taylor AM; Jackson AP; Ogi T; Lehmann AR; Green CM; Crosby AH, 2014. Hypomorphic PCNA mutation underlies a human DNA repair disorder.  J Clin Invest 124(7):3137-46

Matsuse M; Mitsutake N; Tanimura S; Ogi T; Nishihara E; Hirokawa M; Fuziwara CS; Saenko VA; Suzuki K; Miyauchi A; Yamashita S, 2013. Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.  Int J Cancer 132(3):738-43

Kashiyama K; Nakazawa Y; Pilz DT; Guo C; Shimada M; Sasaki K; Fawcett H; Wing JF; Lewin SO; Carr L; Li TS; Yoshiura K; Utani A; Hirano A; Yamashita S; Greenblatt D; Nardo T; Stefanini M; McGibbon D; Sarkany R; Fassihi H; Takahashi Y; Nagayama Y; Mitsutake N; Lehmann AR; Ogi T, 2013. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am J Hum Genet 92(5):807-19

Woodbine L; Neal JA; Sasi NK; Shimada M; Deem K; Coleman H; Dobyns WB; Ogi T; Meek K; Davies EG; Jeggo PA, 2013. PRKDC mutations in a SCID patient with profound neurological abnormalities. J Clin Invest 123(7):2969-80

Ogi T; Nakazawa Y; Sasaki K; Guo C; Yoshiura K; Utani A; Nagayama Y, 2013. [Molecular cloning and characterisation of UVSSA, the responsible gene for UV-sensitive syndrome]. Seikagaku 85(3):133-44

Kashiyama K; Mitsutake N; Matsuse M; Ogi T; Saenko VA; Ujifuku K; Utani A; Hirano A; Yamashita S, 2012. miR-196a downregulation increases the expression of type I and III collagens in keloid fibroblasts.  J Invest Dermatol 132(6):1597-604

Nakazawa Y; Sasaki K; Mitsutake N; Matsuse M; Shimada M; Nardo T; Takahashi Y; Ohyama K; Ito K; Mishima H; Nomura M; Kinoshita A; Ono S; Takenaka K; Masuyama R; Kudo T; Slor H; Utani A; Tateishi S; Yamashita S; Stefanini M; Lehmann AR; Yoshiura K; Ogi T, 2012. Mutations in UVSSA cause UV-sensitive syndrome and impair RNA polymerase IIo processing in transcription-coupled nucleotide-excision repair.  Nat Genet 44(5):586-92

Ogi T; Walker S; Stiff T; Hobson E; Limsirichaikul S; Carpenter G; Prescott K; Suri M; Byrd PJ; Matsuse M; Mitsutake N; Nakazawa Y; Vasudevan P; Barrow M; Stewart GS; Taylor AM; O'Driscoll M; Jeggo PA, 2012. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel Syndrome.  PLoS Genet 8(11):e1002945

Matsumoto Y; Miyamoto T; Sakamoto H; Izumi H; Nakazawa Y; Ogi T; Tahara H; Oku S; Hiramoto A; Shiiki T; Fujisawa Y; Ohashi H; Sakemi Y; Matsuura S, 2011. Two unrelated patients with MRE11A mutations and Nijmegen breakage syndrome-like severe microcephaly.  DNA Repair (Amst) 10(3):314-21

Nakamura K; Kogame T; Oshiumi H; Shinohara A; Sumitomo Y; Agama K; Pommier Y; Tsutsui KM; Tsutsui K; Hartsuiker E; Ogi T; Takeda S; Taniguchi Y, 2010. Collaborative action of Brca1 and CtIP in elimination of covalent modifications from double-strand breaks to facilitate subsequent break repair.  PLoS Genet 6(1):e1000828

Ogi T; Limsirichaikul S; Overmeer RM; Volker M; Takenaka K; Cloney R; Nakazawa Y; Niimi A; Miki Y; Jaspers NG; Mullenders LH; Yamashita S; Fousteri MI; Lehmann AR, 2010. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells.  Mol Cell 37(5):714-27

Nakazawa Y; Yamashita S; Lehmann AR; Ogi T, 2010. A semi-automated non-radioactive system for measuring recovery of RNA synthesis and unscheduled DNA synthesis using ethynyluracil derivatives.  DNA Repair (Amst) 9(5):506-16

Limsirichaikul S; Niimi A; Fawcett H; Lehmann A; Yamashita S; Ogi T, 2009. A rapid non-radioactive technique for measurement of repair synthesis in primary human fibroblasts by incorporation of ethynyl deoxyuridine (EdU).  Nucleic Acids Res 37(4):e31

Sukumar N; Mishra M; Sloan GP; Ogi T; Deora R, 2007. Differential Bvg phase-dependent regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA.  J Bacteriol 189(10):3695-704

Lehmann AR; Niimi A; Ogi T; Brown S; Sabbioneda S; Wing JF; Kannouche PL; Green CM, 2007. Translesion synthesis: Y-family polymerases and the polymerase switch.  DNA Repair (Amst) 6(7):891-9

Takenaka K; Ogi T; Okada T; Sonoda E; Guo C; Friedberg EC; Takeda S, 2006. Involvement of vertebrate Polkappa in translesion DNA synthesis across DNA monoalkylation damage.  J Biol Chem 281(4):2000-4

Ogi T; Lehmann AR, 2006. The Y-family DNA polymerase kappa (pol kappa) functions in mammalian nucleotide-excision repair.  Nat Cell Biol 8(6):640-2

Ogi T; Kannouche P; Lehmann AR, 2005. Localisation of human Y-family DNA polymerase kappa: relationship to PCNA foci.  J Cell Sci 118(Pt 1):129-36

Bavoux C; Leopoldino AM; Bergoglio V; O-Wang J; Ogi T; Bieth A; Judde JG; Pena SD; Poupon MF; Helleday T; Tagawa M; Machado C; Hoffmann JS; Cazaux C, 2005. Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis.  Cancer Res 65(1):325-30

Stafford GP; Ogi T; Hughes C, 2005. Binding and transcriptional activation of non-flagellar genes by the Escherichia coli flagellar master regulator FlhD2C2.  Microbiology 151(Pt 6):1779-88

Wang Y; Seimiya M; Kawamura K; Yu L; Ogi T; Takenaga K; Shishikura T; Nakagawara A; Sakiyama S; Tagawa M; O-Wang J, 2004. Elevated expression of DNA polymerase kappa in human lung cancer is associated with p53 inactivation: Negative regulation of POLK promoter activity by p53.  Int J Oncol 25(1):161-5

Ohmori H; Ohashi E; Ogi T, 2004. Mammalian Pol kappa: regulation of its expression and lesion substrates.  Adv Protein Chem 69:265-78

Schuster M; Lostroh CP; Ogi T; Greenberg EP, 2003. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis.  J Bacteriol 185(7):2066-79

Shimizu T; Shinkai Y; Ogi T; Ohmori H; Azuma T, 2003. The absence of DNA polymerase kappa does not affect somatic hypermutation of the mouse immunoglobulin heavy chain gene.  Immunol Lett 86(3):265-70

Ohashi E; Ogi T; Ohmori H, 2002. [Biochemical studies of human DNA polymerase kappa and its transcriptional regulation].  Seikagaku 74(3):218-23

Ogi T; Shinkai Y; Tanaka K; Ohmori H, 2002. Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene.  Proc Natl Acad Sci U S A 99(24):15548-53

Publication list retrieved from NCBI using ImpactPubs